Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Medigus Ltd. (Nasdaq: MDGS) announced that its 47.69% owned subsidiary, Eventer Technologies Ltd., submitted a draft registration statement on Form F-1 to the SEC for a potential IPO of its shares in the U.S. Eventer specializes in cloud-based ticketing solutions for various events, including in-person, virtual, and hybrid formats. The specific timing, number of shares, and pricing for the offering remain undetermined. This initiative aims to leverage Eventer's innovative technology platform to enhance shareholder value.

Medigus Ltd. (Nasdaq: MDGS) announced promising results from pre-clinical studies conducted by its affiliate, Polyrizon Ltd. Recent findings indicate that Polyrizon's products may prevent interactions between human coronavirus 229E, Influenza Virus H1N1, and epithelial host cells, thereby inhibiting cell death. The company plans to evaluate the efficacy of its innovative product candidate against the Omicron variant (B.1.1.529) in Q1 2022 in collaboration with a professor from Parma University. This highlights the ongoing need for preventive solutions against highly transmissible COVID-19 variants.

Medigus Ltd. (Nasdaq: MDGS) has filed a motion for court approval to increase its buyback program from $2 million to $3 million. This buyback initiative aims to enhance shareholder value and is expected to begin in Q1 2022, contingent upon court approval. The company is involved in advanced medical solutions and innovative technologies, with affiliations in digital commerce and electric vehicle sectors. The successful implementation of the buyback could positively impact stock performance by reducing available shares.

Medigus Ltd. (Nasdaq: MDGS) announced that its 50.03% owned subsidiary, Jeffs’ Brands Ltd., has submitted a draft registration statement to the SEC for a potential initial public offering (IPO) in the U.S. The specifics regarding timing, shares offered, and pricing remain undetermined. This move is part of Jeffs’ Brands’ strategy to enhance its e-commerce capabilities. Medigus, a tech company focusing on medical solutions and digital commerce, supports its affiliates, including Gix Internet and Eventer Technologies, in their market growth endeavors.

Medigus Ltd. (Nasdaq: MDGS) announced a successful procedure using its FDA-approved MUSE™ system, performed by Golden Grand, which was broadcast live on Chinese TV. This milestone in their licensing agreement will result in a total payment of $2.4 million to Medigus, with $600,000 received for this specific procedure. The MUSE™ system, a device for incisionless treatment of gastroesophageal reflux disease (GERD), marks a step in Medigus' strategy to expand its licensing agreements globally.

Medigus Ltd. (MDGS) announced the appointment of Arik Priel as Chief Software Architect and Roee Peled as Vice President of Business Development for ScoutCam Inc., a leader in Industry 4.0 visualization solutions. Priel has over 20 years of experience in R&D and engineering, while Peled specializes in IoT and B2B sales processes. These appointments are aimed at enhancing ScoutCam's capabilities in Predictive Maintenance and expanding its market reach. CEO Yovav Sameah emphasized the need for leadership to drive innovation and adapt the business model towards recurring revenue.

Medigus Ltd. (Nasdaq: MDGS) announced promising pre-clinical data from its affiliate Polyrizon regarding its Capture and Contain (C&C™) hydrogel technology. The data suggests that the lead product candidate, PL-14, has potential to prevent allergic reactions caused by house dust mites and Timothy grass pollen allergens, potentially reducing inflammatory responses. The first efficacy results are anticipated within the next 12 months. Medigus continues to focus on advanced medical solutions and innovative technologies.

Medigus Ltd. (Nasdaq: MDGS) has entered a non-binding MOU with Safee to establish a joint venture focused on the buying and selling of non-fungible tokens (NFTs) and digital assets. Medigus plans to provide up to $5 million in funding for NFT acquisitions and will control the JV's management, appointing three of the four board members. In return for consulting services, Safee may purchase 200,000 shares of Medigus stock at $10 each over the next three years. This partnership aims to broaden the NFT market reach.